PHARMACEUTICAL 2019

XOMA Royalty Corp
Rank 247 of 361



PHARMACEUTICAL 2019

XOMA Royalty Corp
Rank 247 of 361

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 40% points.The greatest weakness of XOMA Royalty Corp is the variable Liabilities, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 189%, being 61% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	47,626
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,703
Liabilities, Non-Current	22,280
Other Assets	16,100
Other Compr. Net Income	0
Other Expenses	2,735
Other Liabilities	17,017
Other Net Income	4,338
Other Revenues	5,299
Property and Equipment	59
Research and Development	1,682
Selling, General and Administrative Expense	18,563

Output Variable	Value in 1000 USD
Assets	63,785
Liabilities	45,000
Expenses	22,980
Revenues	5,299
Stockholders Equity	18,785
Net Income	-13,343
Comprehensive Net Income	-13,343
BaseVar	70,701
ECR before LimitedLiability	51%
Economic Capital Ratio	189%